Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
prostate cancer
Biotech
Candel burns bright as phase 3 cancer win sends stock up 200%
Candel reported a 14.5% relative improvement in disease-free survival, an endpoint that looked at cancer recurrence or death from any cause.
Nick Paul Taylor
Dec 11, 2024 9:49am
FDA OKs AngioDynamics pulsed field ablation for prostate cancer
Dec 10, 2024 10:43am
Chasing Merck, BioNTech, DualityBio post first data on ADC
Dec 6, 2024 9:07am
Janux's T-cell engager makes waves, again, with new data drop
Dec 3, 2024 11:40am
MacroGenics pauses work on ADC pending mature survival data
Nov 6, 2024 4:44am
Essa drops lead cancer drug after falling short against Xtandi
Nov 1, 2024 7:33am
